Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With RDC/TMD Ia and Ib

Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With Research Diagnostic Criteria/Temporomandibular Disorder Ia and Ib (RDC/TMD) Randomized, Double Blinded Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02101632

Acronym

BV/TMD

Enrollment

Registered

2014-04-02

Start date

2014-02-28

Completion date

2014-03-31

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other Disorders of Muscle in Diseases Classified Elsewhere

Keywords

TMD, bee venom, muscle tension, muscle pain

Brief summary

Topical application of BV ointment in patients with Research Diagnostic Criteria/Temporomandibular Disorder 1a and 1b (RDC/TMD) in experimental group, compared to placebo (vaseline) in control group.Application was repeated 3 times a day, during 14 days. Surface electromyography (EMG) was used to measure masseter rest tonus and maximal voluntary contraction tonus. Pain intensity was also analysed in VAS scale. Effectiveness of BV was compared with placebo in masseter myofascial pain in patients with TMD

Detailed description

The aim of the study was evaluation of myorelaxant action of bee venom(BV) ointment, comparing to placebo.Parallel group, randomized double blinded trial was performed, including 79 patients with painful RDC/TMD 1a and 1b. Muscle tension was measured twice (TON1 and TON2) in rest muscle tonus (RMT) and maximal muscle contraction (MMC) on both sides right and left, with Easy Train Myo EMG (Version 3.1). Pain intensity was also analysed in VAS scale

Interventions

DIETARY_SUPPLEMENTBee Venom Ointment

2 weeks

OTHERVaseline Ointment

2 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 79 Years

Healthy volunteers

Inclusion criteria

* RDC/TMD 1a and 1b * agreement to participate in the experimental study

Exclusion criteria

* bee venom allergy * hyperactivity on bee products * positive anamnesis of anaphylactic reaction after bee bites * skin wounds with skin surface discontinuation * RDC/TMD 2 and 3

Design outcomes

Primary

Measure	Time frame	Description
Masseter muscle tension	2 weeks	Masseter muscle tension at rest and in maximal voluntary contraction, electromyographic measurement \[V\]

Secondary

Measure	Time frame	Description
Pain intensity of masseter muscle	2 weeks	Pain intensity evaluation after 2 weeks of physiotherapy in visual analoque scale (VAS) scale

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026